Mihăilă Romeo G
Faculty of Medicine, "Lucian Blaga" University of Sibiu, str Lucian Blaga, nr 2A, Sibiu, 550169 Sibiu, Romania.
Recent Pat Anticancer Drug Discov. 2014;9(3):340-53. doi: 10.2174/1574892809666140327161242.
Resveratrol is a poly-phenol with many beneficial effects: not only as an antioxidant, anti-inflammatory, and antiatherogenic agent, as well as a platelet aggregation inhibitor, but also as an antiproliferative and proapoptotic factor in various types of cancers. There are reviews about the mechanisms responsible for its effects in leukemia and lymphomas, emphasizing the chemosensitizing role of resveratrol, which allows overcoming the multidrug resistance of cancers. The action of resveratrol occurs preferentially on leukemic cells, and not on the normal ones. In addition, it is one of the few drugs that act on leukemic stem cells. If experimental results are promising, its application in humans encounters some difficulties. The paper presents the causes of its low bioavailability, as well as recent patents that allow improvement of its bioavailability, development of new extraction procedures, obtaining new formulae, and associating resveratrol with other drugs in order to increase its effects. These patents allow optimizing its effects in order to obtain an adjuvant agent for treatment of oncohematological disorders.
不仅作为抗氧化剂、抗炎剂和抗动脉粥样硬化剂，以及血小板聚集抑制剂，还作为各种癌症中的抗增殖和促凋亡因子。有关于其在白血病和淋巴瘤中作用机制的综述，强调了白藜芦醇的化学增敏作用，这使得能够克服癌症的多药耐药性。白藜芦醇的作用优先发生在白血病细胞上，而不是正常细胞上。此外，它是少数作用于白血病干细胞的药物之一。如果实验结果很有前景，其在人类中的应用会遇到一些困难。本文介绍了其生物利用度低的原因，以及最近的专利，这些专利允许提高其生物利用度、开发新的提取程序、获得新配方，以及将白藜芦醇与其他药物联合使用以增强其效果。这些专利允许优化其效果，以便获得一种用于治疗血液肿瘤疾病的辅助剂。
